Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $28.9b | $215.50 | +7.0% | 1.4M |
 NBIX | Neurocrine Biosciences Inc | $15.9b | $165.64 | +2.7% | 1.2M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $14.8b | $229.94 | +1.7% | 517.2K |
 AXSM | Axsome Therapeutics, Inc | $12.1b | $244.88 | +1.8% | 1.5M |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $11.8b | $6.38 | -14.8% | 470.2K |
 CYTK | Cytokinetics Inc. | $10.4b | $82.14 | +1.6% | 3.1M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $9.8b | $329.69 | -0.0% | 965.6K |
 ALKS | Alkermes Inc. plc | $7.0b | $54.56 | +4.4% | 2.9M |
 PTCT | PTC Therapeutics, Inc. | $6.1b | $84.40 | -0.2% | 1.5M |
 TGTX | TG Therapeutics, Inc. | $5.8b | $55.50 | +4.1% | 3.1M |
 XENE | Xenon Pharmaceuticals Inc | $5.3b | $60.13 | +5.2% | 3.7M |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.3b | $41.90 | +1.2% | 3.0M |
 ACAD | Acadia Pharmaceuticals Inc. | $3.7b | $25.36 | +6.8% | 4.3M |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.3b | $25.34 | +3.4% | 2.4M |
 ALMS | Alumis Inc. Common Stock | $2.8b | $26.37 | +5.4% | 1.7M |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.7b | $46.85 | +4.7% | 1.1M |
 DFTX | Definium Therapeutics, Inc. Common Shares | $2.6b | $44.90 | +0.2% | 4.6M |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.9b | $31.98 | +5.1% | 1.2M |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.9b | $39.87 | +2.9% | 498.4K |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $1.8b | $35.34 | +4.0% | 786.0K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.7b | $6.28 | +2.3% | 3.7M |
 ATAI | AtaiBeckley Inc. Common Stock | $1.7b | $5.33 | +15.1% | 17.4M |
 BHVN | Biohaven Ltd. | $1.7b | $15.89 | +3.2% | 5.1M |
 GHRS | GH Research PLC Ordinary Shares | $1.6b | $27.50 | +11.2% | 249.3K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $1.6b | $17.79 | +2.0% | 1.3M |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $1.3b | $32.34 | +3.8% | 605.9K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.1b | $36.60 | +4.9% | 726.5K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $5.52 | +6.0% | 5.0M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.9b | $65.50 | +0.7% | 124.5K |
 TBPH | Theravance Biopharma, Inc. | $0.8b | $17.64 | +1.5% | 330.4K |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.8b | $31.86 | +2.9% | 603.3K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $6.68 | +3.1% | 2.4M |
 ANRO | Alto Neuroscience Inc. | $0.7b | $26.93 | +6.9% | 493.6K |
 PRTA | Prothena Corporation plc Ordinary Shares | $0.5b | $9.81 | +8.2% | 786.4K |
 OVID | Ovid Therapeutics Inc. Common Stock | $0.5b | $2.56 | +5.0% | 2.2M |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.5b | $14.19 | +5.8% | 628.1K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.5b | $4.38 | -2.2% | 4.4M |
 VNDA | Vanda Pharmaceuticals Inc. | $387.9m | $6.02 | +2.4% | 658.6K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $342.8m | $1.59 | +7.3% | 2.3M |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $294.1m | $3.81 | +2.5% | 2.8M |
 AVXL | Anavex Life Sciences | $280.8m | $2.60 | +5.9% | 1.2M |
 ACIU | AC Immune SA | $270.7m | $2.56 | +4.3% | 233.2K |
 ALEC | Alector, Inc. Common Stock | $239.8m | $1.87 | +1.1% | 472.9K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $233.8m | $3.58 | +0.8% | 821.2K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $231.1m | $1.85 | +1.1% | 685.9K |
 NERV | Minerva Neurosciences, Inc | $228.8m | $4.38 | +6.3% | 277.0K |
 HELP | Cybin Inc. Common Stock | $227.0m | $6.45 | +8.0% | 2.9M |
 NGEN | NervGen Pharma Corp. Common stock | $219.8m | $1.93 | -3.1% | 909.5K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $196.6m | $12.65 | +10.7% | 954.3K |
 ABOS | Acumen Pharmaceuticals, Inc. Common Stock | $187.8m | $2.32 | +6.8% | 504.0K |